| Předmět: |
|
| Zdroj: |
Cancer Vaccine Week; 2/12/2024, p140-140, 1p |
| Abstrakt: |
Researchers from Bristol-Myers Squibb Company have submitted a patent application for a method of treating tumors using a subcutaneous administration of a pharmaceutical composition containing an antibody that binds to PD-1 or PD-L1. The method involves administering one or more subcutaneous unit doses of the composition, with each dose containing at least 300 mg to 2400 mg of the antibody. The researchers suggest that this method could improve patient compliance compared to intravenous administration. The patent application also describes the use of an auto-injector or wearable pump for administration and mentions that various types of cancer can be treated using this method. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
